• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

This Sleeper Name Could Wake Up in 2020

I see attractive potential for this recent IPO if it can nail down a few new customers.
By JAMES "REV SHARK" DEPORRE
Jan 07, 2020 | 12:30 PM EST
Stocks quotes in this article: PSNL

I've recently discussed two of my top picks for 2020, a small biotechnology name with a good chance of being taken over and a technology company on the leading edge of new developments in the cloud.

A third stock that I believe will do well in 2020 is a sleeper name that has done very poorly since its IPO this past June.

Personalis (PSNL) is a growing genomics company that focuses on "providing comprehensive molecular data about each patient's cancer and immune response."

Currently the company's biggest client is the Veterans Administration. Personalis recently announced a $38.1 million order from the VA's Million Veteran Program. The VA contract produces about half of the company's revenue so this solidifies analyst estimates and sets the stage for upside. In its most recent quarter revenue grew by 47%.

This relationship with the VA is likely to build but what will move the stock in 2002 is its NeXT platform. This platform will be the first that tests for all 20,000 or more cancer genes. This is a potential $5 billion market and creates a long-term, ongoing relationship with customers that use the testing service. Personalis already announced its first customer, which is Merck of Germany.

A good explanation of Personalis' business can be found in the transcript of the second quarter earnings report.

This is not a trade based on a great technical setup. The stock has been beaten up badly due to the poor response to certain IPOs, tax-loss selling and the expiration of the lock-up on insider shares. The combination of these issues has pressured PSNL but it seems to have found support around the $10 area.

I expect that the stock will start to move as it announces some contracts for its NeXT product, but these are large deals with large companies and will take time to negotiate.

Analysts currently have price targets as follows: Morgan Stanley $28, Oppenheimer $29, Bank of America Merrill Lynch $22. So, there appears to be potential for a double or more if the company can nail down a few new customers.

I have a position and will look to add to it incrementally.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Rev Shark was long PSNL.

TAGS: IPOs | Investing | Stocks | Trading

More from Stocks

If You've Got Time, These Three Dividend Aristocrats Should Pay Off

Bob Ciura
Jul 2, 2022 7:30 AM EDT

There high-growth dividend stocks will be here over the long haul.

Welcome to Second Semester on Wall Street, Here's How to Make the Grade

Jim Collins
Jul 1, 2022 4:36 PM EDT

Think you can own big tech? You might just get an 'F' for that. Here's what will get you on the other side of this year.

We Got a Break, but the Heat Is Still On

James "Rev Shark" DePorre
Jul 1, 2022 4:22 PM EDT

A limited rally cooled some of the negativity on the market, but guess what's going to hit the fan soon?

Coupang Could Make a Bigger Trading Bounce

Bruce Kamich
Jul 1, 2022 1:56 PM EDT

Here's where nimble traders could probe the long side.

Shares of Xencor Could Be Bought on a 50% Correction

Bruce Kamich
Jul 1, 2022 11:59 AM EDT

Traders should remain patient.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:59 PM EDT PAUL PRICE

    Very good quarterly numbers from Bassett Furniture (BSET)

    Bassett Furniture (BSET) blew right through analys...
  • 04:41 PM EDT PAUL PRICE

    First Half Results - Putrid Second Half Results - Likely to Be Much Better

    It's great that we're done with June. 2022 marked...
  • 04:51 PM EDT PAUL PRICE

    We Should Be in for Better Starting Soon

    Window dressing Thursday, the last day of the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login